Trial · NCT05745337
Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor
NCT05745337, Phase 1, Unknown, University of Vermont
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor. Trials, record NCT05745337. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05745337
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor
- NCT number
- NCT05745337
- Status
- Unknown
- Phases
- Phase 1
- Enrollment
- 20 participants, estimated
- Lead sponsor
- University of Vermont
- Conditions
- Atrial Fibrillation, Diastolic Dysfunction, HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
- First posted
- 2023-02-27
- Last updated
- 2023-03-03
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Exercise capacity | At time of randomization and 6 months afterwards. | Change in peak oxygen consumption during cardiopulmonary exercise testing |
| Secondary | Number of participants with a composite of treatment related adverse events | At 6 months, at 12 months, at 18 months, at 24 months | Number of heart failure hospitalization, unplanned hospitalization for atrial fibrillation, stroke or transient ischemic attack, acute coronary syndrome in both treatment arms |
| Other | Number of participants with a composite of treatment related heart failure events | At 6 months, at 12 months, at 18 months, at 24 months | Heart failure events: diuretic drug change, emergency room visit |
| Other | Number of participants with a composite of treatment related atrial fibrillation events | At 6 months, at 12 months, at 18 months, at 24 months | Atrial fibrillation events: planned hospitalization, emergency room visit, cardioversion, antiarrhythmic medication initiation |
| Other | Change in quality of life by Minnesota Living with heart failure questionnaire score | At time of randomization and 6 months afterwards. | Score ranges from 0-105 with higher scores meaning worse quality of life |
| Other | Change in quality of life by Atrial fibrillation Effect on Quality of life questionnaire score | At time of randomization and 6 months afterwards. | Score ranges from 0-100 with higher scores meaning better quality of life |
| Other | Change in NTproBNP | At time of randomization and 6 months afterwards. | |
| Other | Change in hsTroponin | At time of randomization and 6 months afterwards. | |
| Other | Change in HbA1c | At time of randomization and 6 months afterwards. | |
| Other | Change in Fructosamine | At time of randomization and 6 months afterwards. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers30
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05745337
GET https://conductscience.org/api/trials/v1/NCT05745337/papers?page=2